Epizyme (EPZM) Getting Somewhat Favorable Press Coverage, Analysis Shows

News headlines about Epizyme (NASDAQ:EPZM) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Epizyme earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.0911305427243 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Epizyme (NASDAQ:EPZM) opened at $13.95 on Wednesday. The firm has a market cap of $976.89, a P/E ratio of -6.15 and a beta of 2.00. Epizyme has a one year low of $9.30 and a one year high of $20.45.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. research analysts predict that Epizyme will post -2.23 EPS for the current year.

EPZM has been the subject of a number of analyst reports. Cann reissued a “buy” rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Oppenheimer reissued a “buy” rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Jefferies Group initiated coverage on shares of Epizyme in a research note on Wednesday, September 20th. They set a “buy” rating and a $23.00 target price for the company. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Monday, October 16th. Finally, Royal Bank of Canada lowered shares of Epizyme from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $20.00 to $16.00 in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $22.40.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 25.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://weekherald.com/2018/01/17/epizyme-epzm-getting-somewhat-favorable-press-coverage-analysis-shows.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply